Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Safety and Cost Effectiveness

Date: Monday, November 14, 2016

Time: 2:30PM-4:00PM

Meeting: 2016 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 1999

Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug

2:30PM-4:00PM: Abstract Number: 2000

Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept

2:30PM-4:00PM: Abstract Number: 1998

Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab

2:30PM-4:00PM: Abstract Number: 1997

Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry

2:30PM-4:00PM: Abstract Number: 2001

Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].